Conexeu Sciences Inc. (CNXU)
Market Closed
15 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM) Primary $
3. 95
+0.3
+8.2192%
$
100.88M Market Cap
- P/E Ratio
- Div Yield
600,300 Volume
- Eps
$ 3.65
Previous Close 
Want to track CNXU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission
Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance by Q1 2027, potentially accelerating market entry to late 2027 and minimizing investor dilution. Current valuation (~$13.20/share) exceeds risk-adjusted fair value ($10.71), but premium is justified by pipeline breadth and upside if regulatory milestones are met.
Seekingalpha | 3 months ago
2026 © Marketlog. All Rights Reserved.
